uploads/2018/01/Analysts-Reco-ATRA-1.png

Where Atara Biotherapeutics Stands This January: Analyst Ratings

By

Updated

Company overview

Incorporated at Delaware in 2012, Atara Biotherapeutics (ATRA) is a company focused on developing novel T-cell immunotherapy treatment options for patients suffering from cancer and multiple sclerosis.

Atara’s allogenic T-cells are engineered from donors with healthy immune functions. This allows for a speedy delivery from inventories to patients (within three to five days) without the requirement of pretreatment. The company’s T-cell immunotherapies are designed to identify and eliminate cancerous cells without affecting healthy cells.

Article continues below advertisement

Analyst ratings

Of the six analysts covering Atara Biotherapeutics in January 2018, four analysts have given the stock a “buy” or a higher rating, while two analysts have given it a “hold” rating. The mean rating for the stock is 1.83, with a target price of $34.2.

Notably, Atara Biotherapeutics makes up about 0.04% of the Vanguard Russell 2000 ETF’s (VTWO) total portfolio holdings.

Peer ratings

By comparison, of the 26 analysts covering Amgen (AMGN) in January 2018, 12 analysts have given the company a “buy” or a higher rating, while 14 analysts have given it a “hold” rating. The mean rating for the stock is 2.35, with a target price of $192.8.

Of the 31 analysts covering Celgene (CELG) in January 2018, 17 analysts have given the stock a “buy” or a higher rating, while 13 analysts have given the stock a “hold” rating, and only one analyst has given it a “sell” rating. The mean rating for the stock is 2.19, with a target price of $123.7.

Of the 23 analysts covering Merck (MRK) in January 2018, 14 analysts have given the stock a “buy” rating, while nine analysts have given it a “hold” rating. The mean rating for the stock is 2.13, with a target price of $66.8.

In the next part of the series, we’ll take a look at Atara Biotherapeutics’ product pipeline.

Advertisement

More From Market Realist